THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Pulendran, Bali
Feng, Yupeng
Abrégé
Provided herein are antibodies and antigen binding fragments that are capable of binding to a betacoronavirus, e.g. a sarbecovirus selected from one or more of SARS-CoV-2, SARS-CoV-2 omicron, SARS-CoV-2 beta, SARS-CoV-1, WIV-1, RaTG13, and SCH014.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Subramanian, Sandya
Coleman, Todd
Nguyen, Linda, A.
Abrégé
Embodiments herein provide systems and methods to identify gastric dysfunction. Many embodiments utilize ECG and/or EGG measurements for an individual to determine autonomic modulation and/or gastric motility modulation. Additional embodiments utilize functional principal components analysis to identify features present in ECG and/or EGG that can distinguish phenotypes (e.g., healthy, dysfunctional, etc.) based on scoring features extracted from ECG and/or EGG trace data. Further embodiments provide diagnostic and/or treatments to the individual based on an identified phenotype.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Cromer, Michael Kyle
Porteus, Matthew H.
Charlesworth, Carsten
Abrégé
The present disclosure provides methods and compositions for tunable differentiation of hematopoietic stem and progenitor cells (HSPCs) in response to small molecules by using genetically modified HSPCs that express chimeric transmembrane receptors.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Desimone, Joseph, M.
Coates, Ian, A.
Lipkowitz, Gabriel, E.
Abrégé
Aspects of the present disclosure include methods for making a polymeric structure having a micro-void space. Methods according to certain embodiments include irradiating a polymerizable composition positioned between a build elevator and a build surface to generate a polymerizable composition having a polymerized region of the polymerizable composition having a micro-void space in contact with the build elevator and a non-polymerized region of the polymerizable composition in contact with the build surface, displacing the build elevator away from the build surface, contacting the generated micro-void space with a non-reactive composition and repeating in a manner sufficient to generate a polymeric structure having a resolved micro-void space. Systems for preparing a polymeric structure according to the subject methods are also described. Polymeric structures having a resolved micro-void space such as where the micro-void space is filled with a non-polymerizable composition are also provided.
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
A61M 37/00 - Autres appareils pour introduire des agents dans le corps; Percutanisation, c. à d. introduction de médicaments dans le corps par diffusion à travers la peau
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Das, Rhiju
Wayment-Steele, Hannah K.
Abrégé
Embodiments herein describe systems and methods to enhance RNA stability and uses thereof. Many embodiments alter the sequence of an RNA therapeutic molecule (e.g., vaccines) to encode for a variant peptide while maintaining and/or increasing stability of the RNA therapeutic.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
6.
SYNTHESIS OF TIGILANOL TIGLATE AND ANALOGS THEREOF
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Wender, Paul A.
Luu, Nguyen Hong Quang
Gentry, Zachary
Njoo, Edward
Fanelli, David
Mcateer, Owen Dennis
Abrégé
Provided are methods for the isolation of phorbol from seed sources and the use of the phorbol for the generation of tigliane tiglate and derivatives thereof.
C07D 303/14 - Composés contenant des cycles oxirane avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène liés par des liaisons simples ou doubles par des radicaux hydroxyle libres
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p.ex. quinones, vitamine K1, anthraline
A61K 36/47 - Euphorbiaceae (famille de l'euphorbe), p.ex. Ricinus (ricin)
7.
DEVICES, SYSTEMS, AND METHODS FOR IMAGING USING SHORTWAVE INFRARED LIGHT
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
HELMHOLTZ ZENTRUM MUENCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (Allemagne)
Inventeur(s)
Park, Roy
Yang, Stella
Valdez, Tulio
Bruns, Oliver
Bischof, Thomas Stanley
Klein, Tjadina-Wencke
Abrégé
Imaging devices, systems, and methods are provided for imaging using narrow bands of short wavelength infrared (SWIR) light, e.g., to image at water absorption wavelength and/or to image through blood. In one example, an imaging device is provided for imaging during a medical procedure that includes a proximal end, a distal end sized for introduction into a subject's body, and an imaging element carried by the distal end, a light source coupled to the imaging device to deliver one or both of narrow band short wavelength infrared (SWIR) light and visible light, and a camera for acquiring images via the imaging element.
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
8.
NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Dever, Daniel P.
Bak, Rasmus O.
Hendel, Ayal
Srifa, Waracharee
Porteus, Matthew H.
Abrégé
In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c. à d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Goldenberg, David
Tzvetanov, Ivan
Abrégé
Gastrostomy tubes and systems and methods for implanting them are provided. In one example, the gastrostomy tube includes an elongate tubular member including a first end sized for introduction into the patient's mouth, a second end including an expandable member or other bumper, and a feeding lumen extending between the first and second ends. A bolster is connectable around the first end after the first end has been directed from within the patient's stomach through intervening tissue and extends from the patient's skin and the bumper is placed against the wall of the stomach. An adapter is connectable to the bolster after the first end and excess material of the tubular member beyond the bolster has been separated, the adapter including a connector for removably connecting to a feeding tube.
The Board of Trustees of the Leland Stanford Junior University (USA)
Novome Biotechnologies, Inc. (USA)
Inventeur(s)
Sonnenburg, Justin L.
Whitaker, Weston R.
Stanley, Elizabeth
Deloache, William C.
Abrégé
Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.
The Board of Trustees of the Leland Stanford Junior University (USA)
CALIFORNIA INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Birnbaum, Michael Edward
Mendoza, Juan Luis
Bethune, Michael Thomas
Baltimore, David
Garcia, Kenan Christopher
Abrégé
Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
12.
DEVICES AND METHODS INVOLVING LOW-TEMPERATURE-GROWN DIAMOND IN ELECTRONIC DEVICES
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Chowdhury, Srabanti
Malakoutian, Mohamadali
Abrégé
In exemplary methods, diamond is grown al low-temperature (e g., under 600° C or under 400° C) is grown. In one aspect, the method includes controlling growth of the diamond, during the diamond growth, by a gas chemistry that abates sp2 carbon formation and enhances diamond grain sizes in both lateral and vertical directions in the diamond while mitigating new diamond grains from forming on top of each other. As another aspect, the low-temperature diamond is grown on a wafer including one or more Si-based semiconductor devices adjacent and sufficiently close to a hot spot in a channel region of the semiconductor device(s) to cause, during operation of the semiconductor device(s), heat to be drawn from multiple sides of the hot spot, without undermining performance during operation of the semiconductor device(s).
13.
LINEAR EXOSKELETON FOR REDUCING KNEE CONTACT FORCE
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Slade, Patrick
Delp, Scott, L.
Robles, Nicholas, Miguel
Abrégé
A wearable robotic device, called linear exoskeleton, is provided. The linear exoskeleton applies active assistance to reduce the knee contact forces during walking. The objective of the exoskeleton is to reduce knee contact force by using a motor to apply forces between a strap on the thigh and the ground. The force applied is controllable. The exoskeleton itself has a linear actuator type design, with a carriage that slides along a carbon pole.
A61F 2/70 - Moyens d'actionnement ou de commande électriques
A61H 3/00 - Appareils pour aider des personnes handicapées à marcher
A63B 23/035 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour les membres, c. à d. supérieurs ou inférieurs, p.ex. en même temps
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Bruno, Michael
Gu Urban, Jijuan
Li-Pook-Than, Jennifer
Slifer, Teri
Snyder, Michael
Abrégé
N-Acylated histidine dipeptides of formula
N-Acylated histidine dipeptides of formula
N-Acylated histidine dipeptides of formula
are disclosed. The compounds are useful for treating breast cancer.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Shin, Chungheon
Criddle, Craig, S.
Tilmans, Sebastien
Abrégé
222, and methane. The gas recovered from an off-gas collection system is beneficially used, such as for energy recovery while minimizing greenhouse gas emissions.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Shin, Giwon
Ji, Hanlee P.
Abrégé
Provided herein is a method that involves lysing cells that have a fusion between a first gene and a second gene at an end of an electrophoresis gel, applying a voltage potential to the gel to intact genomic DNA at one end of the gel, digesting the trapped genomic DNA using two or more pairs of RNA-guided endonucleases to release segments, electrophoresing the segments, eluting the segments into different fractions and analyzing the sequences nucleic acid collected in the fractions to identify a fraction that contains the segments of the first and second genes and a fraction that contains the segment of the gene fusion.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Foley, Joseph W.
Abrégé
The present invention provides modified oligo(dT) primers containing at least one deliberate mismatch within the dT span of the primer which provides improved stability and replicability of the resulting cDNA molecules. In the context of RNA sequencing applications, incorporation of the modified oligo(dT) primers results in fewer sequence reads lost to PCR artifacts and easier detection of the end position of each sequence read.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Suchy, Fabian Patrik
Nakauchi, Hiromitsu
Hsu, Ian
Abrégé
The present invention provides a set of robust, genetic-based assays to screen for common abnormalities that occur in cultured cells utilizing a digital PCR (dPCR) platform.
The Board of Trustees of the Leland Stanford Junior University (USA)
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Mahajan, Vinit
Sun, Young Joo
Velez, Gabriel
Parsons, Dylan
Abrégé
A high-resolution crystallographic structure of the mutant human G267S calpain-5 protease core domain at 2.22 Å resolution is provided. The G267S mutation is associated with hyperactivity of calpain-5 and is linked to the inherited disease, neovascular inflammatory vitreoretinopathy. Methods of using the crystallographic structure in rational design of small molecule drugs that inhibit calpain-5 for treatment of retinal diseases and other diseases associated with calpain-5 hyperactivity are also provided.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Zheng, Yu
Bao, Zhenan
Abrégé
Aspects involve a stretchable composite film including a polymer material having at least a portion of the polymer material being densified through covalently-attached fluorination molecules. In certain specific examples, fluorinated molecules are covalently attached to a surface region, in the form of a layer or film (e.g., polymer semiconductor (PSC) film of a transistor substrate) to facilitate operational stability and/or to encapsulation performance (e.g., stretchability-related performance). In certain other specific examples, the surface region and a fluorinated layer are used in a cooperative configuration to provide stability in the PSC film in one or more harsh environments characterized by one or more of humid air, and immersion of the PSC film in a bio-based fluid.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Blau, Helen M.
Palla, Adelaida R.
Tri Van Ho, Andrew
Abrégé
Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.
A61K 31/5575 - Eicosanoïdes, p.ex. leucotriènes ayant un cycle cyclopentane, p.ex. prostaglandine E2, prostaglandine F2-alpha
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/245 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro du type acide aminobenzoïque, p.ex. procaïne, novocaïne
A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
A61K 31/46 - Aza-8-bicyclo[3.2.1]octane; Ses dérivés, p.ex. atropine, cocaïne
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Anderson, Thomas Anthony
Abrégé
Devices, systems, and methods are provided for relieving peripheral nerve pain in a subject. In one example, the device includes a surface configured for placement against a subject's skin, an imaging element on the housing configured to transmit signals from the surface into the subject's body and receive reflected signals from the body, and one or more transducer elements configured to deliver focused ultrasound from the surface into the body. A controller is coupled to the imaging element to process the reflected signals to identify a target nerve within the body and coupled to the one or more transducer elements to control delivery of the focused ultrasound to the target nerve to relieve pain.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Fordyce, Polly M.
Curtis, Christina
Sockell, Alexandra F.
Wong, Wing
Abrégé
Organoid culture and image-processing methods and systems are described. Such methods and systems provide the ability for high-throughput characterization of a variety of phenotypes at single-organoid resolution.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Qi, Lei S.
Guo, Lucie
Kempton, Hannah
Abrégé
The present disclosure generally relates to engineered Cluster Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated (Cas) 12a proteins and system, and methods for use in gene editing and gene modulation for application to gene therapy. Related systems and methods of gene modulation are also disclosed.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Wender, Paul
Quiroz, Ryan
Ho, Stephen
Shimizu, Akira
Ryckbosch, Steven
Stevens, Matthew C.
Jeffreys, Matthew S.
Hardman, Clayton
Sloane, Jack
Abrégé
Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.
C07D 407/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
C07D 493/22 - Composés hétérocycliques contenant des atomes d'oxygène comme uniques hétéro-atomes dans le système condensé dans lesquels le système condensé contient au moins quatre hétérocycles
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Montine, Thomas J.
Wawro, Adam
Abrégé
Methods of use, pharmaceutical formulations, and labeled versions of compounds are provided of compounds that penetrate the blood-brain barrier and influence the balance of excitatory versus inhibitory neurotransmission by enantiomer selective modulation of glutamate and GABA metabolism. In some embodiments, a glutamatergic false neurotransmitter is S-2-methylglutamate (S-2MeGlu). In some embodiments a GABAergic false neurotransmitters is R-4 aminopentanomic acid (4APA) or S-4 aminopentanomic acid (S-4APA), with high penetration of the blood brain barrier and low toxicity, therein providing useful pharmacologic or imaging agents.
A61K 31/197 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p.ex. acide gamma-aminobutyrique (GABA), bêta-alanine, acide epsilon-aminocaproïque, acide pantothénique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Naughton, Brian Thomas
Harvey, Colin
Schlecht, Ulrich
Hillenmeyer, Maureen Elizabeth
Horecka, Joe
Abrégé
Methods for identifying biosynthetic gene clusters that include genes for producing compounds that interact with specific target proteins are disclosed. Some methods relate to bioinformatics methods for identifying and/or prioritizing biosynthetic gene clusters. Related systems, components, and tools for the identification and expression of such gene clusters are also disclosed.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
C12N 15/79 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
G16B 10/00 - TIC spécialement adaptées à la bio-informatique évolutive, p. ex. construction ou analyse d’arbre phylogénétique
G16B 25/00 - TIC spécialement adaptées à l’hybridation; TIC spécialement adaptées à l’expression de gènes ou de protéines
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
G16B 30/10 - Alignement de séquence; Recherche d’homologie
28.
GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Flynn, Ryan Alexander
Goodman, Brian
Lawlor, Ciaran
Bisaria, Namita
Cummings, Richard D.
Wei, Mohui
Bertozzi, Carolyn R.
Abrégé
The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
29.
A SCREENING PLATFORM FOR ADAR-RECRUITING GUIDE RNAS
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Li, Jin Billy
Jarmoskaite, Inga
Vogel, Paul
Abrégé
The present invention relates to methods for identifying guide RNAs for use in site-directed RNA editing. In particular, the present invention relates to a high-throughput screening method for identifying guide RNAs effective for site directed A-to-I RNA editing, and methods of use for the identified guide RNAs.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Magnusson, Jens Peter
Qi, Lei S.
Abrégé
The present disclosure generally relates to compositions and methods simultaneous, multi-mode gene expression regulation (e.g., simultaneous upregulation and down regulation of multiple target genes). The present disclosure further relates to novel constructs for engineered multiplex CRISPR arrays.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Wernig, Gerlinde
Lerbs, Tristan
Cui, Lu
Deng, Qiwen
De Souza, Cristabelle
Abrégé
Methods are provided for the treatment of cancer and/or fibrosis. It is shown that there is increased CD63 expression both in lung cancer and pulmonary fibrosis, sarcoma, skin fibrosis, liver cancer and liver cirrhosis, NASH and NHFLD, and kidney fibrosis from hypertension and other etiologies. Inhibiting CD63 increases phagocytosis of lung cancer cells and lung fibroblasts; and can eliminates tumor cells and pathogenic fibrosis.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Lee, Jin Hyung
Liu, Qin
Abrégé
Methods, systems, and devices, including computer programs encoded on a computer storage medium are provided for optimizing neurostimulation therapy for treatment of neurological and neurodegenerative diseases. Joint dynamic causal modeling and biophysics modeling are used for optimization of the stimulation targets and parameters. In particular, methods of performing neuromodulation to suppress b-band oscillations in the brain of a subject are provided.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Lee, Jin Hyung
Dadgar-Kiani, Ehsan
Abrégé
Methods, systems, and devices, including computer programs encoded on a computer storage medium are provided for optimizing neurostimulation therapy for treatment of neurological and neurodegenerative diseases. In particular, an algorithm is used to provide a predicted regional pathological density map of neuropathology and predict locations of future spreading. Neurostimulation therapy parameters including the location, strength, and frequency of neurostimulation can be adjusted accordingly to treat neuropathology and reduce aggregation and spreading.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G16H 30/00 - TIC spécialement adaptées au maniement ou au traitement d’images médicales
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Rutledge, Jarod E.
Wyss-Coray, Tony
Lehallier, Benoit
Poston, Kathleen
Abrégé
Methods are provided for the classification, diagnosis, and/or prognosis of an individual who has PD or is suspected to have PD. The method comprises obtaining one or more biological samples from an individual who has or is suspected to have PD, quantifying the amount of one or more PD related polypeptides in the one or more biological samples, and integrating the results of the quantifying step with the age and sex of the individual from whom the biological sample was obtained from to generate a metric that indicates if that individual has PD wherein the integration is performed by a computer comprising software components for data analysis as a program of instructions executable by the computer.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Foley, Joseph W.
Abrégé
The present invention provides methods and related compositions for producing a sequencing ready DNA library in as few as three steps by combining adapter ligation, degradation, fill-in, and amplification of adapter-DNA fragments into a single reaction.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Felsher, Dean W.
Waymouth, Robert, M.
Sledge, George W., Jr.
Mahauad-Fernandez, Wadie, D.
Abrégé
inter aliainter alia, a copolymer, cell penetrating complexes, compositions and methods for the delivery of therapeutic, including small interfering RNA-based therapeutic agents, into a cell and related methods for treating cancer, including breast cancer and triple-negative breast cancer.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes
37.
METHODS FOR MONITORING MOLECULAR BIOMARKERS FOR AGING AND DISEASE
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Mahajan, Vinit
Wolf, Julian
Abrégé
Compositions, methods, and kits are provided for diagnosing vitreoretinal diseases and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of vitreoretinal diseases are also provided.
38.
PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Steyaert, Jan
Pardon, Els
Rasmussen, Soren G.F.
Fung, Juan Jose
Kobilka, Brian
Laeremans, Toon
Abrégé
The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 14/72 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des hormones
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 23/20 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la réflexion de la radiation par les matériaux
G01N 33/566 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
39.
METHODS FOR PROFILING AND QUANTITATING CELL-FREE RNA
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Koh, Lian Chye Winston
Quake, Stephen R.
Fan, Hei-Mun Christina
Pan, Wenying
Abrégé
The invention generally relates to methods for assessing a neurological disorder by characterizing circulating nucleic acids in a blood sample. According to certain embodiments, methods tor assessing a neurological disorder include obtaining RNA present in a blood sample of a patient suspected of having a neurological disorder, determining a level of RNA present in the sample that is specific to brain tissue, comparing the sample level of RNA to a reference level of RNA specific to brain tissue, determining whether a difference exists between the sample level and the reference level, and indicating a neurological disorder if a difference is determined.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
40.
Methods and Systems for Analyzing Nucleic Acid Molecules
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Chabon, Jacob J.
Kurtz, David M.
Diehn, Maximilian
Alizadeh, Arash Ash
Abrégé
Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, nucleic acid molecules, such as cell-free nucleic acids, can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and/or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 25/00 - TIC spécialement adaptées à l’hybridation; TIC spécialement adaptées à l’expression de gènes ou de protéines
G16B 25/20 - Réaction en chaîne par polymérase; Conception d’amorces ou de sondes; Optimisation de la sonde
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
G16B 30/10 - Alignement de séquence; Recherche d’homologie
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
41.
Compositions of Iboga Alkaloids and Methods of Treatment
The Board of Trustees of the Leland Stanford Junior University (USA)
Soneira Inc., P.B.C. (USA)
Inventeur(s)
Williams, Nolan R.
Kratter, Ian
Daniels, Annamarie
Bird, Gregory
Abrégé
Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 33/06 - Aluminium, calcium ou magnésium; Leurs composés
The Board of Trustees of the Leland Stanford Junior University (USA)
Soneira Inc., P.B.C. (USA)
Inventeur(s)
Williams, Nolan R.
Coetzee, John Philip
Geoly, Andrew Dedinas
Daniels, Annamarie
Bird, Gregory
Abrégé
Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 33/06 - Aluminium, calcium ou magnésium; Leurs composés
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
43.
METHODS AND COMPOSITIONS TO CONTROL GENE USING GENOME EDITING
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Engreitz, Jesse
Martyn, Gabriella
Montgomery, Michael
Doughty, Benjamin
Jones, Harold
Guo, Katherine
Abrégé
Provided herein are methods for screening edited genomic sequences for their effect on expression of a target gene, and for designing a target sequence edit for introducing to a target sequence of a nucleic acid molecule. Also provided are compositions and cells including the edited sequences, and methods for their use in preventing or treating a disease.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Moradifar, Parivash
Chinn, Garry
Levin, Craig, S.
Dionne, Jennifer, A.
Kim, Yushin
Abrégé
A Purcell enhanced metamaterial scintillator structure comprises a conducting structure and a dielectric structure disposed adjacent to the conducting structure. The dielectric structure comprises a structure of scintillating nanoparticles.
G01T 1/202 - Mesure de l'intensité de radiation avec des détecteurs à scintillation le détecteur étant du cristal
B82Y 20/00 - Nano-optique, p.ex. optique quantique ou cristaux photoniques
C09K 11/66 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du germanium, de l'étain ou du plomb
45.
INHIBITION OF PROSTAGLANDIN DEGRADING ENZYME 15-PGDH TO IMPROVE JOINT STRUCTURE AND FUNCTION
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Blau, Helen M.
Bhutani, Nidhi
Singla, Mamta
Palla, Adelaida Rosa
Abrégé
The present disclosure provides methods of improving the structure and/or function of a joint tissue of a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating joint dysfunction and/or degeneration associated with aging, injury, disease, disorder, and/or condition.
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p.ex. ticlopidine
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
46.
Inducible Production-Phase Promoters for Coordinated Heterologous Expression in Yeast
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Harvey, Colin
Schlecht, Ulrich
Hillenmeyer, Maureen Elizabeth
Abrégé
Inducible promoters for the coordinated expression of at least one heterologous gene in yeast and methods of using them are disclosed. In particular, the invention relates to sets of inducible promoters derived from S. cerevisiae and related species that can be induced in the presence of nonfermentable carbon sources.
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
47.
SYNERGISTIC STIMULATION OF MUCOCILIARY CLEARANCE TO TREAT MUCUS OBSTRUCTION IN CYSTIC FIBROSIS AND OTHER MUCO-OBSTRUCTIVE DISORDERS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Wine, Jeffrey J.
Joo, Nam Soo
Milla, Carlos E.
Abrégé
The present disclosure provides methods of treating an individual for a muco-obstructive, the methods including: administering to the individual a b-adrenergic agonist or an adenylate cyclase activator, in combination with a cholinergic agonist to treat the individual for the muco-obstructive disorder.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
48.
MULTIPLE ACTUATOR CONTROL ON A SOFT EVERTING ROBOT
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Okamura, Allison M.
Heap, William E.
Kuebler, Alexander M.
Agharese, Nathaniel E.
Abrégé
An independent control method of actuators in for example an everting robot or a soft everting robot is provided. The robot has distributed thereto or therewith multiple actuators which steer the robot. Energy is supplied from a single energy line to each of the multiple actuators. This energy enables force and displacement for each of the multiple actuators. Energy from the single energy line to each of the multiple actuators is controlled by a single control line. The single energy line and the single control line can be pneumatic sources or electric sources. The method allows for controlling greater than two actuators with at most two supply lines instead of one supply line per actuator. Reduction of the number of supply lines and complexity of subsystems provides numerous advantages in terms of cost, size, stiffness, friction, amount of material used, ease for tip mounts as well as mobility.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Cohen, Stanley N.
Xu, Weijing
Feng, Yanan
Abrégé
Methods of treating a subject for a cellular proliferative disease, e.g., a cancer, are provided. Aspects of the methods include: administering to the subject an agent that modulates DSIF complex activity, e.g., activity of a DSIF complex made up of a SPT4 and SPT5 protein, such as a DSIF complex made up of Supt4h and Supt5h, in a manner sufficient to treat the subject for the cellular proliferative disease. Also provided are compositions for practicing the methods.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Gaudilliere, Brice
Hedou, Julien
Verdonk, Franck
Abrégé
Embodiments herein describe systems and methods to generate a risk score for an individual to develop postoperative neurocognitive disorder (POND). Various embodiments obtain multi-omics data from an individual, such as genomics, transcriptomics, and proteomics. In certain embodiments, a machine learning algorithm is used to generate the risk score based on the multi-omics data. In further embodiments, clinical data is further used in the determination of the risk score.
G06N 20/20 - Techniques d’ensemble en apprentissage automatique
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
51.
METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY
The Board of Trustees of the Leland Stanford Junior University (USA)
University of California, San Francisco (USA)
Inventeur(s)
Saper, Vivian E.
Mellins, Elizabeth D.
Hollenbach, Jill
Abrégé
Provided herein are, inter alia, methods for treating subjects in need of an IL-1 inhibitor therapy or an IL-6 inhibitor therapy, and related methods. The methods include determining whether the subject is at risk for drug-related hypersensitivity by assaying for the presence of certain HLA alleles.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
52.
METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Liddelow, Shane
Guttenplan, Kevin
Barres (deceased), Ben
Abrégé
The present disclosure relates to methods of inhibiting reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in a subject. In one embodiment, the method involves administering an inhibitor of Elongation of Very Long Chain Fatty Acids Protein 1 (ELOVL1) to a subject having or at risk of having a condition mediated by reactive astrocytes, where the ELOVL1 inhibitor is administered in an amount effective to inhibit reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in the subject. In another embodiment, the method involves administering an inhibitor of lipoapoptosis to a subject having or at risk of having a condition mediated by reactive astrocytes, where the inhibitor of lipoapoptosis is administered in an amount effective to inhibit reactive astrocyte mediate neuronal and/or oligodendrocyte cell death in the subject.
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/201 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p.ex. acides oléique ou linoléique
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
53.
CHEMICALLY REVERSIBLE 2`-OH ACYLATION PROTECTS RNA FROM HYDROLYTIC AND ENZYMATIC DEGRADATION
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Fang, Linglan
Kool, Eric T.
Abrégé
Compositions and methods are provided for the reversible modification of RNA to enhance RNA in-solution and enzymatic stability by reaction with acylimidazoles, sulfonyltriazoles, or sulfonylimidazoles. 2′-OH acylation protects RNA from hydrolytic and enzymatic degradation. Water-soluble organocatalysts can accelerate the reversal of acylation adducts and functionally restore RNAs, alternatively the acylation is spontaneously reversed in a cellular environment. Chemically tuned 2′-OH acylation can be spontaneously released in cells to restore RNA biological functions including translation. mRNA can be selectively modified at the 2′-OH of poly(A)-tail for enhanced in-cell stability and enhanced total protein output.
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
54.
ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2
The Board of Trustees of the Leland Stanford Junior University (USA)
Parker Institute for Cancer Immunotherapy (USA)
Inventeur(s)
Garcia, Kenan Christopher
Parker, Sean
Sockolosky, Jonathan
Hollander, Michael
Abrégé
Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Agrawal, Shashank
Bünz, Karl Benedikt
Zamani, Mahdi
Boneh, Dan
Abrégé
Blockchain-based, smart contract platforms have great promise to remove trust and add transparency to distributed applications. However, this benefit often comes at the cost of greatly reduced privacy. Techniques for implementing a privacy-preserving smart contract is described. The system can keep accounts private while not losing functionality and with only a limited performance overhead. This is achieved by building a confidential and anonymous token on top of a cryptocurrency. Multiple complex applications can also be built using the smart contract system.
G06Q 20/38 - Architectures, schémas ou protocoles de paiement - leurs détails
G06Q 20/06 - Circuits privés de paiement, p.ex. impliquant de la monnaie électronique utilisée uniquement entre les participants à un programme commun de paiement
G06Q 20/36 - Architectures, schémas ou protocoles de paiement caractérisés par l'emploi de dispositifs spécifiques utilisant des portefeuilles électroniques ou coffres-forts électroniques
H04L 9/00 - Dispositions pour les communications secrètes ou protégées; Protocoles réseaux de sécurité
H04L 9/06 - Dispositions pour les communications secrètes ou protégées; Protocoles réseaux de sécurité l'appareil de chiffrement utilisant des registres à décalage ou des mémoires pour le codage par blocs, p.ex. système DES
H04L 9/32 - Dispositions pour les communications secrètes ou protégées; Protocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
56.
COMPOSITION AND METHOD OF UNIVERSAL PSEUDOTYPED RETROVIRUSES
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Qi, Lei S.
Chavez, Michael
Finn, Paul B.
Abrégé
Provided herein are retroviral vector systems useful for producing universal pseudotyped retroviruses for cell and gene therapies. The vector systems include an envelope plasmid and a packaging plasmid, where at least one of these plasmids encodes a binding moiety that directly binds a target cell through a cell binding domain, or that indirectly binds a target cell through an antibody binding domain. Also provided are related retrovirus-packaging cells, retroviruses, virus-like particles, and methods for their production and use in preventing or treating a disease.
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Santa Maria, Peter Luke
Steenerson, Kristen K.
Fan, Danyang
Kargotich, Stephen
Liang, Bradley C.
Persche, Julia
Abrégé
A method for assessing fatigue of a subject is provided. The method includes providing a device comprising a first electrode, a second electrode, and a circuit operably coupled to the first and second electrodes, the first and second electrodes configured to detect an electrical activity associated with an eye blink of a subject, and the circuit is configured to process a signal from the first electrode and the second electrode; determining a blink event based on the electrical activity; and assessing a degree of fatigue of the subject, based on the blink event. A headset including circuitry, such as a processor and a memory storing instructions to cause the headset to perform the above method are also provided. Also provided are systems and kits that include the devices. The methods, devices, headsets, systems and kits find use in a variety of different applications.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Pavel-Dinu, Mara
Porteus, Matthew H.
Abrégé
The present disclosure provides methods and compositions for treating SCID-X1 in subjects, comprising genetically modifying cells from the subjects ex vivo by integrating a full-length, codon-optimized IL2RG cDNA at the endogenous IL2RG locus.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Sun, Zhanghao
Quan, Ronald
Solgaard, Olav
Abrégé
In certain examples, methods and apparatuses, such as circuits, are directed to scanning in a field of view (FoV) by using a pattern that improves sensing in a region of interest (RoI) within the FoV. In one example, a signal having multiple frequency components and a scan-pattern design are used, with a balanced or optimized set of attributes including a sampling density attribute, to scan a RoI in a FoV by sampling or traversing the RoI more times than other regions in the FoV. In more specific examples, circuitry finds the scan-pattern design based on an algorithm that processes different parameters involving at least one of amplitude and phase and processes a. number of different frequency components related to or including the multiple frequency components, wherein the number of different frequency components is from three to a threshold limit whereat processing different frequency components provides negligible improvement.
G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie
B81B 7/02 - Systèmes à microstructure comportant des dispositifs électriques ou optiques distincts dont la fonction a une importance particulière, p.ex. systèmes micro-électromécaniques (SMEM, MEMS)
G01S 7/481 - Caractéristiques de structure, p.ex. agencements d'éléments optiques
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Majeti, Ravindra
Weissman, Irving L.
Abrégé
Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
62.
IMMUNOGENIC CORONAVIRUS FUSION PROTEINS AND RELATED METHODS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
CZ BIOHUB SF, LLC (USA)
Inventeur(s)
Powell, Abigail E.
Weidenbacher, Payton Anders-Benner
Friedland, Natalia
Sanyal, Mrinmoy
Tang, Shaogeng
Kim, Peter S.
Abrégé
Provided are fusion proteins including an amino acid sequence of an ectodomain of Spike protein of a coronavirus, such as SARS-CoV-2, joined to an amino acid sequence of a ferritin subunit polypeptide. Nanoparticles including such fusion proteins, with surface-exposed trimers of the ectodomain of the Spike protein of the coronavirus, are also provided. Also provided are nucleic acids and vectors encoding the fusion proteins, cells containing such nucleic acid and vectors, immunogenic compositions including the fusion proteins, the nanoparticles, or the vectors, as well as corresponding methods and kits.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
SONEIRA INC., P.B.C. (USA)
Inventeur(s)
Williams, Nolan, R.
Kratter, Ian
Daniels, Anna Marie
Bird, Gregory
Abrégé
Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.
A61K 31/135 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p.ex. quinuclidine
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
SONEIRA INC., P.B.C. (USA)
Inventeur(s)
Williams, Nolan, R.
Coetzee, John, Philip
Geoly, Andrew, Dedinas
Daniels, Anna Marie
Bird, Gregory
Abrégé
Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
65.
COMPOSITIONS AND METHODS FOR ASSESSING KINASE ACTIVITY
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Su, Yichi
Lin, Michael Z.
Wu, Yan
Abrégé
Provided are nucleic acids encoding kinase-modulated bioluminescent indicator (KiMBI) polypeptides. In certain embodiments, a nuclei acid of the present disclosure encodes a KiMBI polypeptide comprising a first bioluminescent enzyme fragment, a phospho-binding domain, a 5 second bioluminescent enzyme fragment capable of forming an active bioluminescent enzyme with the first fragment via enzyme fragment complementation, and a kinase substrate bound by the phospho-binding domain when phosphorylated. KiMBI polypeptide may be fused to one or more fluorescent proteins, e.g., which exhibit resonance energy transfer (RET). Also provided are KiMBI polypeptides encoded by the nucleic acids of the present disclosure. Cells that express 10 a KiMBI polypeptide are also provided, as are non-human animals comprising such cells. Also provided are methods of assessing activity of a kinase of interest in a non-huma animal, and methods of assessing a test agent for the ability to inhibit a kinase of interest in a non-human animal.
C12Q 1/66 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une luciférase
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
66.
SYSTEMS AND METHODS FOR ALTERING THE SHAPE OF NASAL TISSUES
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
The United States Government as represented as The Department of Veterans Affairs (USA)
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Kintzing, James
Mccutcheon, Brandon
Nayak, Jayakar V.
Abrégé
Systems and methods are provided for altering the shape of a target tissue structure of a subject, e.g., a nasal septum or other nasal tissue that include securing a first end of a shaping element to tissue adjacent the structure; manipulating the tissue to alter a shape of the structure; and applying a force to the shaping element to maintain the altered shape of the structure.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Williams, Nolan R.
Maron-Katz, Adi
Abrégé
Systems and methods for neuronavigation in accordance with embodiments of the invention are illustrated. Targeting systems and methods as described herein can generate personalized stimulation targets for the treatment of mental conditions. In many embodiments, direct stimulation of a personalized the stimulation target indirectly impacts a brain structure that is more difficult to reach via the stimulation modality. In various embodiments, the mental condition is major depressive disorder. In a number of embodiments, the mental condition is suicidal ideation.
A61B 34/20 - Systèmes de navigation chirurgicale; Dispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p.ex. pour la stéréotaxie sans cadre
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
A61N 1/20 - Application de courants électriques par électrodes de contact courants continus ininterrompus
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Mackall, Crystal
Majzner, Robbie
Labanieh, Louai
Lin, Michael
Abrégé
Provided are recombinant polypeptides that comprise a protein of interest, a protein localization tag, and a protease cleavage site disposed between the protein of interest and the protein localization tag. In certain embodiments, the recombinant polypeptides further comprise a protease, where the protease cleavage site is a cleavage site for the protease. Also provided are nucleic acids that encode the recombinant polypeptides, cells that comprise such nucleic acids, and compositions (e.g., pharmaceutical compositions) that comprise such cells. Methods of regulating cellular localization of a protein of interest, and methods of administering a regulatable cell-based therapy to an individual in need thereof, are also provided.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
69.
BATTERY MANAGEMENT SYSTEM FOR DETERMINING A HEALTH OF A POWER SOURCE BASED ON AN IMPEDANCE INDICATOR
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Negoita, Gianina Alina
Paxton, William Arthur
Allam, Anirudh
Onori, Simona
Pozzato, Gabriele
Pulvirenti, Luca
Abrégé
A method is provided. The method includes determining an open circuit voltage of a battery of a vehicle. The method also includes determining a voltage of a current provided to the battery of the vehicle. The method further includes determining a impedance indicator based on the voltage, the open circuit voltage, and the current provided to the battery of the vehicle. The method further includes determining a health of the battery based on the impedance indicator.
G01R 31/392 - Détermination du vieillissement ou de la dégradation de la batterie, p.ex. état de santé
G01R 31/3842 - Dispositions pour la surveillance de variables des batteries ou des accumulateurs, p.ex. état de charge combinant des mesures de tension et de courant
G01R 31/389 - Mesure de l’impédance interne, de la conductance interne ou des variables similaires
70.
Indirect Liftoff Mechanism for High-Throughput, Single-Source Laser Scribing for Perovskite Solar Modules
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Flick, Austin
Dauskardt, Reinhold H.
Abrégé
A vertically selective liftoff scribing process is provided. One application is the fabrication of solar cells and solar modules. The basis of this technology is absorption of an indirectly focused laser beam in the front electrode material of the device, which enables removal of this layer (e.g., a P1 scribe) or removal of layers above the front electrode while leaving the front electrode intact (e.g., a P2 or P3 scribe). The laser fluence can be selected to choose between these alternatives, and further fine tuning is possible depending on details of the device structure.
H01L 31/0463 - Modules PV composés d'une pluralité de cellules solaires en couches minces déposées sur un même substrat caractérisés par des méthodes spéciales de structuration pour connecter les cellules PV dans un module, p.ex. gravure par laser des couches conductrices ou des couches actives
B23K 26/0622 - Mise en forme du faisceau laser, p.ex. à l’aide de masques ou de foyers multiples par commande directe du faisceau laser par impulsions de mise en forme
B23K 26/40 - Enlèvement de matière en tenant compte des propriétés du matériau à enlever
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Bassik, Michael C.
Kamber, Roarke A.
Gu, Mingxin
Abrégé
The present disclosure provides methods for treating a disease or disorder or enhancing phagocytosis of a target cell. The methods comprise administering or contacting an immune cell with an inhibitor of paired immunoglobulin-like type 2 receptor-alpha (PILRA).
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
72.
FAST-CHARGING OF HYBRID LITHIUM-ION / LITHIUM-METAL ANODES BY NANOSTRUCTURED HARD CARBON FLOWER HOST
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Gong, Huaxin
Chen, Yuelang
Cui, Yi
Bao, Zhenan
Abrégé
The present embodiments relate generally to stable cycling of metallic lithium under high current densities and realistic cell conditions based on a flower-like nanostructured hard carbon host (CF). In embodiments, CF is both intercalated with lithium ions and plated with lithium metal to render a hybrid lithium-ion/lithium-metal anode capacity. The hybrid cells showed >99% CE up to 12 mA/cm2(4 mAh/cm2) and >99.5% CE up to 16 mA/cm2(2.5 mAh/cm2) with commercial carbonate electrolyte. The stability of the hybrid anodes was attributed to uniform lithium plating morphology and fast ion diffusion pathways enabled by the open-pore nanostructures of CF. Moreover, the CF||NMC811 hybrid cells (2 mAh/cm2) showed excellent performance (~70% capacity retention after 200 cycles, 100% SOC, room temperature) at 10 mA/cm2 current densities (<20 min charging for 100% SOC), while demonstrating ~4 times anode specific capacity and much better cyclic stability compared to graphite] |NMC lithium-ion cells at such current.
H01M 4/13 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p.ex. liants, charges
H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif
73.
INTEGRATED LASER STABILIZATION WITH BUILT-IN ISOLATION
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
White, Alexander
Ahn, Geun, Ho
Van Gasse, Kasper
Vuckovic, Jelena
Abrégé
Laser feedback stabilization combined with isolation is provided in an integrated approach. The main element is a high quality factor resonator that acts as a circulator under high optical power due to the Kerr nonlinearity. This resonator can then be coupled to a laser or optical gain media to provide isolation and combined with a feedback path to stabilize the lasing mode.
H03G 3/12 - Commande actionnée manuellement dans des amplificateurs non accordés comportant des dispositifs à semi-conducteurs comprenant la contre-réaction
74.
ADJUVANTS TO STIMULATE BROAD AND PERSISTENT INNATE IMMUNITY AGAINST DIVERSE ANTIGENS
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Pulendran, Bali
Wimmers, Florian
Abrégé
Methods are provided herein for modulating the epigenome of immune cells by administration of an immunostimulatory composition comprising adjuvants, e.g. vaccine adjuvants, to stimulate broad and persistent innate immunity against pathogens unrelated to antigens present in the composition.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
76.
HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Liu, Jie
Weissman, Irving L.
Majeti, Ravindra
Abrégé
Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
77.
CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Qi, Lei S.
Dingal, P.C. Dave P.
Abrégé
The present disclosure provides systems, compositions and methods for regulating expression of a target polynucleotide in a cell. The systems, compositions and methods comprise a chimeric receptor polypeptide comprising a G-protein coupled receptor (GPCR) or a fragment thereof, a chimeric adaptor polypeptide, at least one actuator moiety and a cleavage moiety.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Rensi, Stefano Emanuele
Abrégé
Systems and methods for generating knowledge graphs and text summaries from document databases are provided. In one embodiment, a system for generating knowledge graphs and text summaries includes: a device, including: a processor; and a memory containing a knowledge graph and text summary generating application, where the knowledge graph and text summary generating application directs the processor to: query a global network of biomedical relationships; construct a knowledge graph and a citation graph; apply processes to learn local context-based weights and compute summarizations; and provide results via a display.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Silva Manzano, Daniel Adriano
Yu, Shawn
Ulge, Umut
Baker, David
Garcia, Kenan Christopher
Spangler, Jamie
Walkey, Carl
Rubio, Alfredo Quijano
Jude, Kevin
Weitzner, Brian
Abrégé
De novo designed polypeptides that bind to IL-2 receptor βγc heterodimer (IL-2Rβγc), IL-4 receptor αγc heterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
The Board of Trustees of the Leland Stanford Junior University (USA)
The United States Government as Represented by The Department of Veterans Affairs (USA)
Inventeur(s)
Goldberg, Jeffrey L.
Cameron, Evan
Abrégé
The present invention relates to a method for selectively transducing retinal and optic nerve head (ONH) astrocytes using adeno-associated virus serotype 5 (AAV5) in combination with a modified glial fibrillary acidic protein promoter (gfaABC1D) for delivery of gene therapies (recombinant DNA, shRNA, Crispr/Cas9) to treat glaucoma or other optic neuropathies
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Chang, Howard Y.
Greenleaf, William J.
Chen, Xingqi
Buenrostro, Jason
Abrégé
Methods for labeling and imaging the accessible genome using a transposase are disclosed. In some embodiments, a bifunctional transposase complex or transposome is used to insert adaptors comprising chemical tags selectively at accessible sites in the genome where active regulatory DNA is located. Various chemical tags can be used for labeling DNA at insertion sites, including, for example, fluorescent dyes for fluorescence imaging, metal particles for electron microscopy or magnetic manipulation of DNA, isotopic labels, or biotin or other ligands, haptens, substrates, or inhibitors that are recognized by streptavidin, antibodies, enzymes, or receptors. Labeling DNA in this manner can be used to provide spatial information regarding the positioning of regulatory DNA in the genome and makes possible the imaging and sorting of cells based on the status of their regulatory DNA.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Bogyo, Matthew S.
Verdoes, Martijn
Ofori, Leslie
Withana, Nimali P.
Abrégé
Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.
G01N 33/532 - Production de composés immunochimiques marqués
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07K 5/065 - Dipeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p.ex. Phe, Tyr
C09B 23/01 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique
C09B 23/08 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre impair de groupes CH plus de trois groupes CH, p.ex. polycarbocyanines
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
83.
SALT-PHILIC SOLVENT-PHOBIC (SP2) INTERFACIAL COATINGS FOR ANODES
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Bao, Zhenan
Cui, Yi
Huang, Zhuojun
Lai, Jiancheng
Abrégé
A salt-philic solvent-phobic (SP2) polymer coating on a lithium anode, sodium anode, or a silicon anode selectively transports salt over solvent and is configured to promote salt-derived SEI formation on the anode. The SP2 coating can include a polymer backbone, a first side chain comprising a first moiety having salt affinity, and a second side chain comprising a second moiety immiscible with polar aprotic solvents.
C08F 220/06 - Acide acrylique; Acide méthacrylique; Leurs sels métalliques ou leurs sels d'ammonium
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p.ex. liants, charges
H01M 4/134 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de métaux, de Si ou d'alliages
H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif
84.
COMPOSITIONS AND METHODS FOR TRANSGLUTAMINASE-MEDIATED ENDOCYTOSIS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Khosla, Chaitan
Loppinet, Elise
Besser, Harrison
Abrégé
in vivo ex vivo ex vivo delivery of a molecular cargo into endo-lysosomal compartments of LRP1-expressing cells. A molecular cargo of interest is linked to a substrate or inhibitor for recognition and transport via human transglutaminase 2 (TG2).
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p.ex. thromboplastine, aminopeptidase de la leucine (3.4)
C12N 9/64 - Protéinases provenant de tissu animal, p.ex. rennine
85.
COMPOSITIONS AND METHODS FOR MODULATING GROWTH OF A GENETICALLY MODIFIED GUT BACTERIAL CELL
The Board of Trustees of the Leland Stanford Junior University (USA)
Novome Biotechnologies, Inc. (USA)
Inventeur(s)
Sonnenburg, Justin L.
Whitaker, Weston R.
Stanley, Elizabeth
Deloache, William C.
Abrégé
Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Davis, Mark M.
Mallajosyula, Venkata Vamsee Aditya
Abrégé
An antigen-specific T cell binding agent is provided, where a multivalent ‘spheromer’ system utilizes a scaffold of a self-assembling polypeptide nanoparticle, for example using selfassembling ferritin polypeptides. The system is compatible with current pMHC reagents, including both MHC-I and MHC-II molecules, and streptavidin reagents that allow ease-of-use. The spheromer assembly pipeline provides a consistent reagent across multiple batches of synthesis with ease of production. The defined geometry of the scaffold allows precise site-directed conjugation of pMHC, leading to a homogenous reagent. The spheromer binds cognate TCRs with a significantly higher avidity than a tetrameric reagent.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Chandran Suja, Vineeth
Fuller, Gerald G.
Calhoun, Suzanne G. K.
Abrégé
Miscible antifoams are provided that do not separate out of a target liquid and that are easy to incorporate in the target liquid. A method or system involves mixing a liquid (‘a miscible antifoam’) into a target foaming liquid. This miscible antifoam is engineered/chosen such that it has both a higher surface tension and is more volatile than the target liquid, or engineered such that it has both a lower surface tension and is less volatility than the target liquid. The miscible antifoam leads to surface tension gradients that cause bubble rupture up to 10 times faster than the target liquid without the antifoam. Further, the miscible antifoams are easy to incorporate and do not separate out from the target liquid during operation—both of which are key limitations faced by existing antifoams.
C10M 169/00 - Compositions lubrifiantes caractérisées en ce qu'elles contiennent comme constituants un mélange d'au moins deux types d'ingrédients, couverts par les groupes précédents, choisis parmi les matériaux de base, les épaississants ou les additifs, chacun
B01D 19/04 - Dispersion ou prévention de la mousse par addition de substances chimiques
C10L 1/08 - Combustibles carbonés liquides à base essentielle de mélanges d'hydrocarbures pour allumage par compression
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Pachynski, Russell
Kohrt, Holbrook
Yonehiro, Jason
Zabel, Brian
Abrégé
The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Hu, Yang
Abrégé
Injection of silicon oil (SO) to the anterior chamber of an eye efficiently induces intraocular pressure (TOP) elevation. This effect occurs without causing overt ocular structural damage or inflammatory responses while simulating acute glaucomatous changes that human patients develop over years by inducing progressive RGC and ON degeneration and visual functional deficits within weeks. The anterior segments of the experimental eyes are not substantially affected, leaving clear ocular elements that allow easy and reliable assessment of in vivo visual function and morphology. More importantly, this is the only reversible ocular hypertension model by removing SO from the anterior chamber and particularly useful for testing neuroprotection treatment together with lowering TOP treatment. In summary, the acute ocular hypertension glaucoma model replicates secondary post-operative glaucoma. It is straightforward and reversible, does not require special equipment or repeat injections, and may be applicable to a range of animal species with only minor modifications.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Garcia, Kenan Christopher
Saxton, Robert
Abrégé
Compositions and methods are provided for preventing or treating obesity and/or overweight, and managing body weight. Compositions comprise partial agonists of the leptin receptor (lepr), including variant leptin polypeptides, which partial agonists elicit sub-maximal signaling at saturating ligand concentrations, and bias the response to STAT3 signaling. Human leptin protein variants, for example leptin modified to increase affinity at site 2 binding site(s) and decrease binding at site 3 binding site(s), preferentially suppress phosphorylation of SHP2, ERK, and STAT1 relative to STAT3, resulting in a biased signal that selectively activates pathways associated with satiety, with decreased activation of pathways associated with leptin resistance. The variant proteins find use in the suppression of appetite, and can provide for therapeutic weight loss.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
NTT RESEARCH, INC. (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Nehra, Rajveer
Yanagimoto, Ryotatsu
Hamerly, Ryan
Ng, Edwin
Marandi, Alireza
Mabuchi, Hideo
Abrégé
Methods and systems are presented for using optical parametric amplifiers in various ways that enhance a native quadratic coupling strength so that a photonic component of interest can be measured or otherwise observed without demolishing the component of interest at a system output. For example such components may include a number of signal Bogoliubov excitations, a pump modular quadrature, or a signal quadrature squared.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
G06N 10/60 - Algorithmes quantiques, p.ex. fondés sur l'optimisation quantique ou les transformées quantiques de Fourier ou de Hadamard
G06N 10/80 - Programmation quantique, p.ex. interfaces, langages ou boîtes à outils de développement logiciel pour la création ou la manipulation de programmes capables de fonctionner sur des ordinateurs quantiques; Plate-formes pour la simulation ou l’accès aux ordinateurs quantiques, p.ex. informatique quantique en nuage
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Khlystov, Nikita
Cochran, Jennifer, R.
Abrégé
Provided are methods of assessing an enzyme for plastic-degrading activity. In certain embodiments, the methods comprise contacting a plastic with the enzyme under conditions suitable for plastic-degrading enzyme activity, and assessing for degradation of the plastic by the enzyme. Also provided are plastic-degrading enzymes and methods of using the same. As a non-limiting example, the plastic-degrading enzymes are polyester-degrading enzymes. As an example, polylactic acid (PLA)-degrading enzymes and methods of using the same. As another example, polyethylene terephthalate (PET)-degrading enzymes and methods of using the same.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C08J 11/10 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p.ex. dévulcanisation
C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
A61K 39/215 - Coronaviridae, p.ex. virus de la bronchite infectieuse aviaire
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
H01J 49/16 - Sources d'ions; Canons à ions utilisant une ionisation de surface, p.ex. émission thermo-ionique ou photo-électrique
95.
ORTHODONTIC DEVICES AND SYSTEMS AND METHODS FOR USING SUCH DEVICES
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Choo, Hyeran
Abrégé
Devices and methods for treating obstructive sleep apnea, habitual mouth breathing, and/or myofunctional therapy includes a body including an anterior end, a posterior end, and lateral portions shaped for introduction into a subject's oral cavity to position the anterior end adjacent front teeth of the subject and the posterior end adjacent the pharyngeal airway of the subject with or without the posterior end adjacent the pharyngeal airway. Sensors and/or stimulators may be provided, to generate electrical current, chemical release, vibration, and/or other stimulations, e.g., to activate neuromuscular contraction, stimulate salivation and subsequent swallowing movement, and/or induce partial wakefulness of the subject and/or to record data regarding the subject's tongue movements and/or position. Optionally, an extraoral sensor device may be provided for placement around the face, nose, check, abdomen, or neck, which may be paired with the intraoral device to detect the respiratory effort related airway obstruction.
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
96.
GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES
The Board of Trustees of the Leland Stanford Junior University (USA)
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Siprashvili, Zurab
Nguyen, Ngon T.
Marinkovich, M. Peter
Tang, Jean
Lane, Alfred T.
Khavari, Paul A.
Abrégé
Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
97.
Nanosecond imaging methods using optical modulators
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Bowman, Adam
Kasevich, Mark A.
Klopfer, Brannon
Abrégé
Improved resolution of a time-varying optical measurement is provided with optical intensity modulator(s) having a bandwidth greater than that of the detector array(s). The modulator configuration can have high photon collection efficiency, e.g. by using polarization modulation to split the incident light into several time-gated channels.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Bekale, Laurent
Santa-Maria, Peter Luke
Abrégé
Compositions, methods, and kits are provided for treating infections and cancer with metallic nanoclusters. In particular, metallic nanoclusters having a size of less than 10 nm that are conjugated to adenosine triphosphate (ATP) or an analogue thereof can be used to eradicate a cell in a growth arrest phase such as infectious bacterial or fungal cells. Such nanoclusters can also induce endoplasmic reticulum stress and inhibit growth of cancerous cells. Additionally, such metallic nanoclusters can be used to inhibit a purinergic P2X7 receptor and FtsH protease.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
99.
COMPOSITIONS AND METHODS FOR TREATING CARDIOMYOPATHIES
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
UNIVERSITY OF CINCINNATI (USA)
Inventeur(s)
Sadek, Hesham, A.
Wang, Ping
Ahmed, Mahmoud, Salama
Wu, Joseph, Ching-Ming
Sadayappan, Sakthivel
Abrégé
Compositions and methods for treating a cardiomyopathy, such as dilated cardiomyopathy (DCM) are provided. Embodiments of the present disclosure provide compositions having a bisphosphonate compound, wherein the compound acts as a structure-based corrector therapeutic by targeting a genetic mutation associated with familial DCM.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p.ex. phosphate de pyridoxal
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Labanieh, Louai
Mackall, Crystal
Majzner, Robbie
Abrégé
Provided are nucleic acids encoding chimeric cytokine receptors (CCRs) capable of signaling in the absence of their cognate cytokines. In some embodiments, provided are one or more nucleic acids encoding a first subunit of a chimeric cytokine receptor and a second subunit of the chimeric cytokine receptor. The first subunit comprises a first heterologous dimerization domain and a first cytokine receptor intracellular signaling domain (ICD). The second subunit comprises a second heterologous dimerization domain cognate for the first heterologous dimerization domain, and a second cytokine receptor ICD. The CCRs find use in a variety of contexts, including but not limited to, increasing the persistence of therapeutic cells. Accordingly, also provided are methods of administering a cell-based therapy, the methods comprising administering therapeutic cells (e.g., CAR-T cells, etc.) expressing the CCRs to a subject in need thereof.
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique